Zacks.com on MSN23h
Merck Halts Second PAH Drug Study Early on Strong Efficacy ResultsMerck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback